Brief: Biomea Fusion Announces Health Canada Clearance of Clinical Trial Application (CTA) for BMF-219 in Type 1 Diabetes
05/12/2023 13:33
Dec 5 (Reuters) - Biomea Fusion Inc BMEA.O :
* BIOMEA FUSION ANNOUNCES HEALTH CANADA CLEARANCE OF
CLINICAL
TRIAL APPLICATION (CTA) FOR BMF-219 IN TYPE 1 DIABETES
* BIOMEA FUSION INC - HEALTH CANADA CLEARED INITIATION OF
COVALENT-112, A PHASE II CLINICAL TRIAL OF BMF-219 IN ADULTS
LIVING WITH TYPE 1 DIABETES (T1D)
Source text for Eikon: ID:nGNX8kfr5D
Further company coverage: BMEA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Biomea Fusion
See all newsUS RESEARCH ROUNDUP-BlackRock, Microsoft, TransDigm Group
Brief: Biomea Fusion Announces Phase 1 Results For Bmf-650, Its Investigational Next-Generation Oral Small Molecule Glp-1 Receptor Agonist
Brief: Biomea Fusion To Announce Phase I Results For Bmf-650, Its Next-Generation Oral Small-Molecule Glp-1 Receptor Agonist
Brief: Biomea Fusion Announces Termination Of Proposed Public Offering Of Securities
Brief: Biomea Fusion Announces Completion Of Enrollment In Covalent-211 Phase Ii Trial Of Icovamenib In Insulin-Deficient Type 2 Diabetes